Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Iboctadekin |
INN | iboctadekin |
Description | Iboctadekin is a protein pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Protein |
Drug class | interleukins |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >4HJJ:H|Anti-IL12 Anti-IL18 DFab Heavy Chain
EVTLRESGPALVKPTQTLTLTCTFSGFSLSKSVMGVSWIRQPPGKALEWLAHIYWDDDKYYNPSLSARLTISKDTSKNQV
VLTMTNMDPVDTATYYCARRGIRSAMDYWGQGTTVTVSSASTKGPEVQLVQSGTEVKKPGESLKISCKGSGYTVTSYWIG
WVRQMPGKGLEWMGFIYPGDSETRYSPTFQGQVTISADKSFNTAFLQWSSLKASDTAMYYCARVGSGWYPYTFDIWGQGT
MVTVSSASTKGPSVFPLAPSSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS
SSLGTQTYICNVNHKPSNTKVDKKVEPK
>4HJJ:L|Anti-IL12 Anti-IL18 DFab Light Chain
DIVMTQSPDSLAVSLGERATINCKASQSVSNDVAWYQQKPGQPPKLLIYYASNRYTGVPDRFSGSGSGTDFTLTISSLEA
EDVAVYYCQQDYNSPWTFGGGTKVEIKRTVAAPEIVMTQSPATLSVSPGERATLSCRASESISSNLAWYQQKPGQAPRLF
IYTASTRATDIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPSITFGQGTRLEIKRTVAAPSVFIFPPSDEQLK
SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT
KSFNRGE |